

# Lodovica Zullo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3189943/publications.pdf>

Version: 2024-02-01

8  
papers

185  
citations

1478280  
6  
h-index

1588896  
8  
g-index

8  
all docs

8  
docs citations

8  
times ranked

220  
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiomic Detection of EGFR Mutations in NSCLC. <i>Cancer Research</i> , 2021, 81, 724-731.	0.4	57
2	Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2625.	1.8	38
3	Metabolic Parameters as Biomarkers of Response to Immunotherapy and Prognosis in Non-Small Cell Lung Cancer (NSCLC): A Real World Experience. <i>Cancers</i> , 2021, 13, 1634.	1.7	23
4	Exploring Response to Immunotherapy in Non-Small Cell Lung Cancer Using Delta-Radiomics. <i>Cancers</i> , 2022, 14, 350.	1.7	22
5	Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 367-383.	1.0	21
6	The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab. <i>Cancers</i> , 2021, 13, 3117.	1.7	17
7	A Circulating Risk Score, Based on Combined Expression of Exo-miR-130a-3p and Fibrinopeptide A, as Predictive Biomarker of Relapse in Resectable Non-Small Cell Lung Cancer Patients. <i>Cancers</i> , 2022, 14, 3412.	1.7	4
8	Safety and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer: focus on challenging populations. <i>Immunotherapy</i> , 2021, 13, 509-525.	1.0	3